Eli Lilly (LLY): What Does the Company Do? – Stock Outlook, Earnings, Market Cap, Related Stocks, Headquarters
Eli Lilly (LLY) is a global large-cap pharmaceutical company whose portfolio includes the obesity and diabetes treatments Mounjaro and Zepbound. It is a mega-cap healthcare company whose stock has been driven by both revenue growth from obesity therapies and clinical progress in its oncology and neuroscience pipelines, with headquarters in the United States.
🏢 What kind of company is Eli Lilly?
Eli Lilly (LLY) is a leading U.S. pharmaceutical company founded in 1876 by Eli Lilly in Indianapolis, Indiana. Beginning as a pioneer in the commercialization of insulin, the company has continued to develop medicines across a wide range of therapeutic areas, including diabetes, endocrinology, oncology, immunology, and neuroscience. More recently, its obesity and diabetes treatment franchise has emerged as the central driver of revenue growth.
The company supplies prescription medicines for diabetes and obesity (Mounjaro, Zepbound, Trulicity), oncology (Verzenio), immunology, and neuroscience to markets worldwide. Its pipeline strategy combines in-house R&D with acquisitions and in-licensing to maintain a steady cadence of new drug launches.
💰 How does Eli Lilly make money?
| Business Segment | Revenue Share | Description |
|---|---|---|
| Diabetes & Obesity Therapies | Largest Growth Driver | Obesity and diabetes treatment franchise: Mounjaro, Zepbound, Trulicity |
| Oncology | Core Franchise | Anticancer agents including Verzenio |
| Immunology | Diversification Driver | Immunology treatments such as Taltz and Olumiant |
| Neuroscience & Other | Complementary Business | Alzheimer's disease, pain, and endocrinology treatments |
Revenue growth from the obesity and diabetes treatment franchise is the central engine of company-wide growth, with global demand for Mounjaro and Zepbound and capacity expansion serving as the main variables shaping the revenue trajectory. The oncology, immunology, and neuroscience portfolio provides revenue diversification and helps cushion cyclical swings. Operating margins vary with the mix of newer drugs and the scale of R&D and capacity investments, while operating leverage is coming into focus as the obesity drug market expands.
📐 Eli Lilly market cap and company scale
Market cap stands at $1.09T, and the workforce is 50,000명.
As a mega-cap pharmaceutical company, Eli Lilly ranks among the world's largest companies by market capitalization and is part of the global leadership group in the obesity and diabetes drug market. It shares the obesity drug market's duopoly with Novo Nordisk (NVO). Backed by stable excess free cash flow and a long track record of dividend increases, the company continues to pursue share buybacks and return capital through dividends while also making large-scale capacity investments to expand obesity drug production.
📈 Eli Lilly outlook and stock price trajectory
Growing demand for obesity and diabetes treatments, capacity additions, the next-generation obesity drug candidates retatrutide and orforglipron, and the global rollout of the Alzheimer's therapy donanemab (Kisunla) are the key medium- to long-term growth drivers. Label expansions for oncology and immunology drugs are also contributing to revenue diversification. Over the near term, obesity drug manufacturing bottlenecks, new competitors, drug pricing pressure, shifts in the FDA approval schedule, and changes in insurance reimbursement and coverage policies can all create volatility.
- Revenue growth and capacity additions for obesity and diabetes drugs
- Next-generation obesity drug candidate pipeline
- Global prescription growth for Alzheimer's and oncology drugs
⚔️ Eli Lilly core strengths and risks
A first-mover position in the obesity drug market and a broad pipeline are key strengths, while manufacturing bottlenecks, intensifying competition, and drug pricing pressure are the core risks.
💪 Core Strengths
⚠️ Core Risks
🔄 Eli Lilly competitors and related (beneficiary) stocks
Direct competitors in the same healthcare category include NVO (Novo Nordisk) in obesity and diabetes drugs, MRK (Merck), PFE (Pfizer), and BMY (Bristol Myers Squibb) in large-cap pharmaceuticals, oncology, and immunology, as well as ABBV (AbbVie), which has a broad portfolio. Related biotechnology and drug-development names include REGN, AMGN, and VRTX, which tend to move alongside developments in the drug pipeline.
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| NVO | Novo Nordisk ADR | $51.61 | +0.1% | $173.3B | 12.1 | 7.3 | 73.79% | 3.46% |
| MRK | Merck & Co Inc | $129.79 | -0.4% | $320.6B | 36.5 | 7.0 | 18.97% | 2.52% |
| PFE | Pfizer Inc | $24.91 | -0.9% | $142.0B | 19.1 | 1.6 | 8.29% | 6.91% |
| BMY | Bristol-Myers Squibb Co | $64.86 | +2.8% | $132.4B | 18.2 | 6.6 | 38.84% | 3.89% |
| ABBV | Abbvie Inc | $257.41 | -2.2% | $454.8B | 127.0 | - | 15221.82% | 2.67% |
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals Inc | $738.34 | +6.2% | $77.4B | 18.0 | 2.5 | 14.55% | 0.53% |
| AMGN | AMGEN Inc | $387.64 | +0.0% | $209.2B | 27.0 | 22.8 | 101.32% | 2.63% |
| VRTX | Vertex Pharmaceuticals Inc | $481.69 | -0.3% | $122.3B | 28.6 | 6.3 | 24.2% | - |
✅ Eli Lilly investor checklist
Key points to monitor when investing in Eli Lilly include obesity drug revenue, capacity expansion, clinical results for next-generation obesity and Alzheimer's pipeline candidates, and drug pricing pressure, all of which are key near- and medium-term variables.
| Checklist Item | What to Verify | Current Status |
|---|---|---|
| 💊 Obesity Drug Revenue | Global revenue trajectory and market-share trend for Mounjaro and Zepbound | Expanding trend |
| 🏭 Capacity Expansion | Obesity drug capacity capex and production throughput | Expanding trend |
| 🔬 Pipeline | Clinical progress for next-generation obesity, Alzheimer's, and oncology drugs | Multiple late-stage trials in progress |
| 💰 Capital Return | Dividend increases and share buyback trend | Steady return trend |
The pace at which obesity drug manufacturing bottlenecks are resolved, new products from direct obesity competitors, and the outcomes of U.S. drug-price negotiations are near-term margin variables. Failures in major late-stage clinical readouts and FDA approval delays can also affect valuation multiples, while changes in insurance reimbursement and coverage policies can affect prescription volumes.
Eli Lilly is positioned as a mega-cap healthcare core holding that combines a first-mover position in obesity drugs with a broad pipeline. Capacity expansion and clinical results for next-generation drugs are the key variables to watch. Staggered purchases and a long-term perspective are recommended.
이 글은 2026년 5월 21일 기준 정보입니다.